Purdue Research May Lead to Therapy That Delays Onset, Reduces Severity of MS Symptoms

Stuart SchlossmanMS Research Study and Reports

March 14, 2011


WEST LAFAYETTE, Ind.–People suffering from multiple sclerosis may benefit if patent-pending research conducted at Purdue University shows that a decades-old drug approved by the FDA to treat hypertension also delays the onset and reduces the severity of MS symptoms.

 
Purdue professor Riyi Shi is examining the effects of hydralazine on acrolein, a compound that can affect the central nervous system and damage nerve cells. Acrolein reacts with proteins and lipids that make up cells, including neurons. Hydralazine sequesters acrolein and acrolein-protein compounds, leading to their expulsion from the body.
Shi’s research focuses on discovering the effective dosage levels to combat acrolein.
“Hydralazine usage in pediatric patients is 7.5 mg per kg of body weight, but we began testing at a much lower ratio: 1 mg per kg of body weight, which has turned out to be effective in delaying the onset of symptoms and lowering their severity in an animal model of MS,” he said. “We have discovered that this dosage level does not cause a significant blood pressure drop or other side effects associated with using higher dosage levels for extended periods of time. We expect that potential use in human MS patients would be at significantly lower doses than the treatment for hypertension.”
Hydralazine therapy for MS is not ready for clinical usage said Shi, a medical doctor and a professor of neuroscience and biomedical engineering in Purdue’s Department of Basic Medical Sciences, School of Veterinary Medicine, Center for Paralysis Research and Weldon School of Biomedical Engineering.
Shi’s first study, published in the journal Neuroscience, tested hydralazine’s effectiveness before MS symptoms developed. He will follow up with studies to identify optimal treatment timing and dosage.
“We currently are testing to see if hydralazine can reduce symptoms if treatment starts after they begin,” he said. “If the drug continues to prove effective, we have good reason to think it might be useful in human MS patients.”

****************************************************************
Providing You with ‘MS Views and News’is what we do
.
Remain CURRENT with educational information of
 Multiple Sclerosis when registered at
the MS Views and News  website.
***************************************************************************************
 Please donate  – all contributions are tax deductible –
***************************************************************************************
Disclaimer:  ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews